hemotune AG

hemotune AG is a Swiss medical technology company focused on developing advanced blood purification technologies that integrate biomedicine and nanotechnology. Founded in 2017 as a spin-off from ETH Zurich, hemotune aims to enhance patient outcomes in critical illnesses, particularly sepsis, through innovative medical devices. The company's flagship product, the HemoSystem, utilizes nanoengineered magnetic beads to selectively bind and remove harmful substances from the bloodstream. This system operates similarly to dialysis, offering improved efficiency and precision compared to traditional blood purification methods. hemotune primarily serves the Swiss healthcare market, with plans for global expansion as it progresses through clinical trials and regulatory approvals. With significant funding and recognition as one of Switzerland's Top Innovative Companies in 2024, hemotune is well-positioned to make a meaningful impact in healthcare. The company is supported by a diverse management team and scientific advisors from leading institutions, ensuring that its product development is grounded in cutting-edge research.

• Employees 23
• Founded 2017
• Annual Revenue $4300000
• Total Funding $29761015